阿莫西林-克拉维酸钾与阿莫西林的不良反应对比分析

Comparative analysis of adverse reactions between amoxycillin-clavulanate potassium and amoxicillin

目的对阿莫西林-克拉维酸钾与阿莫西林的不良反应进行比较。方法回顾性分析我院应用阿莫西林-克拉维酸钾与阿莫西林治疗的15 628例患者的临床资料,依据患者应用药物的不同分为阿莫西林组7 814例及阿莫西林-克拉维酸钾组7814例,比较应用两种药物的不良反应发生情况。结果阿莫西林组不良反应发生率(2.07%)高于阿莫西林-克拉维酸钾组(0.72%),不良反应持续时间长于阿莫西林-克拉维酸钾组,不良反应治疗后对原疾病的影响(14.20%)高于阿莫西林-克拉维酸钾组(3.57%),差异有统计学意义(P<0.05)。结论与阿莫西林相比,阿莫西林-克拉维酸钾在临床应用中,不良反应较少,且症状持续时间短,对原疾病治疗的影响少,较为安全。

Objective To compare the adverse reactions between amoxycillin-clavulanate potassium and amoxicillin. Methods The clinical data of 15 628 cases of patients in our hospital treated with amoxicillin and amoxicillin-clavulanate potassium were retrospectively analyzed, and the patients were divided into amoxicillin group with 7 814 cases and amoxicillin with clavulanate-clavulanate potassium group with 7 814 cases according to different therapeutic drugs. The adverse reactions of the two drugs were compared. Results The occurrence rate of adverse reactions in the amoxicillin group （2.07%） was higher than that in the clavulanate-clavulanate potassium group （0.72%）, and the duration of adverse reactions in the amoxicillin group was longer than that in the amoxicillin-clavulanate potassium group, and the impact of adverse reactions on the original disease after treatment （14.20%） was higher than that of amoxicillin-clavulanate potassium group （3.57%）, with significant differences （P〈0.05）. Conclusion Compared with amoxicillin, the clinical application of amoxycillin- clavulanate potassium has fewer adverse reactions, with short duration of symptoms and less impact on the original disease, which is more secure.